Free Trial

Regeneron Pharmaceuticals (REGN) Competitors

Regeneron Pharmaceuticals logo
$547.15 -0.59 (-0.11%)
As of 01:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

REGN vs. AMGN, GILD, MRNA, NTLA, VIR, VRTX, ABBV, LLY, MRK, and PFE

Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), Vir Biotechnology (VIR), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.

Regeneron Pharmaceuticals vs. Its Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.80$4.09B$10.9627.21
Regeneron Pharmaceuticals$14.20B4.16$4.41B$39.2813.95

Regeneron Pharmaceuticals has a net margin of 31.94% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Regeneron Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen17.39% 176.11% 12.39%
Regeneron Pharmaceuticals 31.94%15.27%11.93%

In the previous week, Amgen had 24 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 60 mentions for Amgen and 36 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.02 beat Regeneron Pharmaceuticals' score of 0.84 indicating that Amgen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
44 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Regeneron Pharmaceuticals
20 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Positive

Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.6%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Regeneron Pharmaceuticals pays out 9.0% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen currently has a consensus target price of $307.82, indicating a potential upside of 3.23%. Regeneron Pharmaceuticals has a consensus target price of $813.57, indicating a potential upside of 48.49%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.35
Regeneron Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.80

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.8% of Amgen shares are held by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Amgen and Regeneron Pharmaceuticals tied by winning 10 of the 20 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REGN vs. The Competition

MetricRegeneron PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$59.30B$2.90B$5.50B$9.03B
Dividend Yield0.66%2.64%5.39%4.11%
P/E Ratio13.9821.4127.5220.10
Price / Sales4.16279.21397.84108.06
Price / Cash11.7041.4736.1356.90
Price / Book2.047.457.985.65
Net Income$4.41B-$55.05M$3.16B$248.47M
7 Day Performance5.16%2.83%1.91%2.80%
1 Month Performance12.30%5.56%4.17%5.62%
1 Year Performance-46.50%6.39%35.76%21.20%

Regeneron Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REGN
Regeneron Pharmaceuticals
4.9419 of 5 stars
$547.15
-0.1%
$813.57
+48.7%
-47.6%$59.07B$14.20B13.9315,106Trending News
Analyst Downgrade
AMGN
Amgen
4.273 of 5 stars
$277.80
+0.2%
$307.82
+10.8%
-4.5%$149.38B$33.42B25.3528,000Positive News
GILD
Gilead Sciences
4.8478 of 5 stars
$110.70
+0.0%
$110.55
-0.1%
+63.0%$137.70B$28.74B23.3117,600Positive News
Insider Trade
MRNA
Moderna
4.3732 of 5 stars
$27.58
+1.5%
$46.61
+69.0%
-74.1%$10.67B$3.24B-3.165,800Options Volume
NTLA
Intellia Therapeutics
4.6677 of 5 stars
$9.41
-1.6%
$33.37
+254.6%
-51.6%$974.69M$57.88M-1.80600
VIR
Vir Biotechnology
3.2188 of 5 stars
$5.10
-1.4%
$32.86
+544.3%
-38.6%$705.02M$74.21M-1.21580News Coverage
Insider Trade
VRTX
Vertex Pharmaceuticals
4.6655 of 5 stars
$444.67
+0.8%
$511.62
+15.1%
-3.5%$114.19B$11.02B-113.446,100Positive News
ABBV
AbbVie
4.9144 of 5 stars
$185.52
+1.8%
$211.29
+13.9%
+14.9%$327.70B$56.33B78.9555,000Trending News
Analyst Revision
LLY
Eli Lilly and Company
4.9897 of 5 stars
$776.15
+0.1%
$1,011.61
+30.3%
-14.1%$735.59B$45.04B63.1547,000Positive News
MRK
Merck & Co., Inc.
4.9971 of 5 stars
$79.02
-0.1%
$109.19
+38.2%
-35.5%$198.42B$63.92B11.5075,000Positive News
PFE
Pfizer
4.8839 of 5 stars
$24.23
+0.2%
$29.17
+20.4%
-9.0%$137.76B$63.63B17.5681,000Trending News

Related Companies and Tools


This page (NASDAQ:REGN) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners